Company Filing History:
1 out of 832,880 Years Active: 2003
Title: Thiery Boon-Falleur: Innovator in Tumor Antigen Research
Introduction
Thiery Boon-Falleur is a notable inventor based in Brussels, Belgium. He has made significant contributions to the field of immunology, particularly in the isolation of cytotoxic T lymphocyte (CTL) clones. His work focuses on advancing cancer treatment through innovative methodologies.
Latest Patents
Boon-Falleur holds a patent for "Tumor antigens and CTL clones isolated by a novel procedure." This invention pertains to the isolation of CTL clones that are specific for MAGE-1 and MAGE-4 antigens. The process involves successive steps of stimulating and testing lymphocytes with antigen-presenting cells that present antigens derived from various expression systems, including recombinant Yersinia, recombinant Salmonella, and recombinant viruses. The patent also covers the MAGE-1 and MAGE-4 antigenic peptides, as well as the peptide/HLA complexes recognized by the isolated CTL clones. He has 1 patent to his name.
Career Highlights
Throughout his career, Boon-Falleur has demonstrated a commitment to advancing cancer immunotherapy. His innovative approaches have positioned him as a key figure in the research community. His work has the potential to significantly impact the treatment of tumors by harnessing the body's immune response.
Collaborations
Boon-Falleur has collaborated with notable colleagues such as Pascal Chaux and Rosalie Luiten. These partnerships have fostered a collaborative environment that enhances research outcomes and drives innovation in the field.
Conclusion
Thiery Boon-Falleur is a distinguished inventor whose work in tumor antigen research is paving the way for new cancer therapies. His innovative patent and collaborative efforts highlight his dedication to improving patient outcomes through scientific advancement.